Mexico

AI Citation Summary

• Country: Mexico
• Product line: Medical devices
• Regulator / source: Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
• Local requirement: Mexico medical-device entry should be separated into COFEPRIS regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 130 million (2024), Latin America's second-largest economy
• Healthcare system: Layered structure — IMSS (Instituto Mexicano del Seguro Social, covering formal-sector workers), ISSSTE (government employees), and Pemex/military medical systems; IMSS-Bienestar (formerly Insabi) covers the uninsured population; the private sector is growing rapidly
• Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
• Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction

Market-Entry Logic

Mexico medical-device entry should be separated into COFEPRIS regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	COFEPRIS	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	IMSS, ISSSTE, INSABI / IMSS-Bienestar transition, public tenders and private hospital networks	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	multinational medtech companies, local importers, hospital distributors, Grupo Ángeles, Christus Muguerza and public procurement channels	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: COFEPRIS digitisation, third-party review history, public procurement reform, nearshoring, distributor control and private hospital growth are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Primary authority: COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), under the SSA (Secretaría de Salud)
• Official portal: https://www.gob.mx/cofepris; electronic filing: SINARETT (Sistema Nacional de Registros de la SSA); https://tramites.cofepris.gob.mx
• Key regulations:
  • Ley General de Salud (General Health Law)
  • Reglamento de Insumos para la Salud (Health Supplies Regulation, RIS)
  • NOM-137-SSA1-2008 (requirements for medical devices and IVDs)
  • NOM-240-SSA1-2012 (post-market surveillance)
  • NOM series standards (technical requirements by product category)
  • Acuerdo de clasificación de dispositivos médicos (device classification agreement)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Description
Clase I	Low risk	EU Class I / FDA Class I	Some products are exempt from registration or follow a simplified notification-only pathway
Clase II	Moderate risk	EU Class IIa-IIb / FDA Class II	Registro Sanitario, standard pathway
Clase III	High risk	EU Class III / FDA Class III	Registro Sanitario, most stringent review; complete technical documentation required

Note: Classification is based on risk level and invasiveness; the FDA classification code cross-reference table may be used as a guide. COFEPRIS has published an official classification directory. IVDs follow separate classification rules.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.